Psoriatic Arthritis Therapeutics Market Global & North America Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Mar 2019| TMR1424A| Transparency

Report Highlights

Psoriatic Arthritis Therapeutics Market - Overview

This report by Transparency Market Research analyses the global psoriatic arthritis therapeutics market for the period between 2018 and 2026. An in-depth and unbiased market assessment has been made, which offers readers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in research & development, manufacture, and marketing of products prescribed in the treatment of psoriatic arthritis.

The global psoriatic arthritis therapeutics market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The global psoriatic arthritis therapeutics market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global psoriatic arthritis therapeutics market for 2017. The report also provides detailed company profiles of emerging market players operating in the global psoriatic arthritis therapeutics market.

The market overview section comprises impact factors such as key market dynamics, including drivers, restraints, and opportunities, affecting the global psoriatic arthritis therapeutics market. These factors are likely to aid stakeholders establish a strong foothold in the global psoriatic arthritis therapeutics market. Furthermore, the market overview section comprises key industry events, pipeline analysis, key mergers & acquisitions across the industry, epidemiology analysis of the psoriatic arthritis, product portfolio overview of leading players, and market attractiveness analysis in the global psoriatic arthritis therapeutics market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market.

Scope

The global psoriatic arthritis therapeutics market has been segmented based on drug class, route of administration, distribution channel, and region. In terms of drug class, the global market has been classified into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others. Based on route of administration, the global market has been segregated into oral, parenteral, and topical. In terms of distribution channel, the global psoriatic arthritis therapeutics market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

In terms of region, the global psoriatic arthritis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global market in various regions has been provided in this section.

The report provides a detailed outline/blueprint of the global psoriatic arthritis therapeutics market, which is expected to assist new companies establish their presence and companies to expand their share in the market. The report concludes with the company profiles section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments of key players.

Competitive landscape

Major players operating in the global psoriatic arthritis therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc.,  Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company.

The global psoriatic arthritis therapeutics market has been segmented into:

Global Psoriatic Arthritis Therapeutics Market, by Drug Class
TNF Inhibitors
Interleukin Inhibitors
PDE4 Inhibitors
Others
 
Global Psoriatic Arthritis Therapeutics Market, by Route of Administration
Oral
Parenteral
Topical
 
Global Psoriatic Arthritis Therapeutics Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
 
Global Psoriatic Arthritis Therapeutics Market, by Region
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

  • Table 1 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 2 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
  • Table 3 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 4 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 5 : North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 6 : North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 7 : North America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
  • Table 8 : North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 9 : Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 10 : Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 11 : Europe Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
  • Table 12 : Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 13 : Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 14 : Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 15 : Asia Pacific Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
  • Table 16 : Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 17 : Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 18 : Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 19 : Latin America Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
  • Table 20 : Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 21 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 22 : Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 23 : Middle East & Africa Psoriatic Arthritis Therapeutics Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
  • Table 24 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Figure 1 : Global Psoriatic Arthritis Therapeutics Market Snapshot
  • Figure 2 : Global Psoriatic Arthritis Market Value (US$ Mn) and Distribution, by Region, 2017 and 2025
  • Figure 3 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 4 : Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class (2017)
  • Figure 5 : Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration (2017)
  • Figure 6 : Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel (2017)
  • Figure 7 : Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Region (2017)
  • Figure 8 : Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 9 : Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 10 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2016–2026
  • Figure 11 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2016–2026
  • Figure 12 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2016–2026
  • Figure 13 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
  • Figure 14 : Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2026
  • Figure 15 : Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
  • Figure 16 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2016–2026
  • Figure 17 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2016–2026
  • Figure 18 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2016–2026
  • Figure 19 : Global Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 20 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
  • Figure 21 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
  • Figure 22 : Global Psoriatic Arthritis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016–2026
  • Figure 23 : Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 24 : Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region 2017 and 2026
  • Figure 25 : Global Psoriatic Arthritis Therapeutics Market Attractiveness, by Region, 2018–2026
  • Figure 26 : North America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 27 : North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country, 2017 and 2026
  • Figure 28 : North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Country, 2018–2026
  • Figure 29 : North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
  • Figure 30 : North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 31 : North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
  • Figure 32 : North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
  • Figure 33 : North America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 34 : North America Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 35 : Europe Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 36 : Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 37 : Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 38 : Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
  • Figure 39 : Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 40 : Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
  • Figure 41 : Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
  • Figure 42 : Europe Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 43 : Europe Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 44 : Asia Pacific Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 45 : Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 46 : Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 47 : Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
  • Figure 48 : Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 49 : Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
  • Figure 50 : Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
  • Figure 51 : Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 52 : Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 53 : Latin America Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 54 : Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 55 : Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 56 : Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
  • Figure 57 : Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 58 : Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
  • Figure 59 : Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
  • Figure 60 : Latin America Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 61 : Latin America Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 62 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 63 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 64 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 65 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Drug Class, 2017 and 2026
  • Figure 66 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
  • Figure 67 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Route of Administration, 2017 and 2026
  • Figure 68 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Route of Administration, 2018–2026
  • Figure 69 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 70 : Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 71 : Global Psoriatic Arthritis Therapeutics Market Share Analysis, by Company (2017)
  • Figure 72 : AbbVie, Inc’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
  • Figure 73 : AbbVie, Inc’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 74 : AbbVie, Inc’s Breakdown of Net Sales (%), by Region
  • Figure 75 : Johnson & Johnson Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
  • Figure 76 : Breakdown of Net Sales (%), by Business Segment, (2017)
  • Figure 77 : Johnson and Johnson R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
  • Figure 78 : Johnson & Johnson Breakdown of Net Sales (%), by Geography (2017)
  • Figure 79 : Novartis AG’s Breakdown of Net Sales, by Geography (2017)
  • Figure 80 : Novartis AG’s Breakdown of Net Sales, by Business Segment (2017)
  • Figure 81 : Novartis AG’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
  • Figure 82 : Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2017
  • Figure 83 : Amgen Inc’s R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017
  • Figure 85 : Amgen Inc’s Breakdown of Net Sales, by Region, 2017
  • Figure 86 : Celgene Corporation’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 87 : Celgene Corporation’s Breakdown of Net Sales (%), by Key Product (2017)
  • Figure 88 : Celgene Corporation’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
  • Figure 89 : Celgene Corporation’s Breakdown of Net Sales, by Geography (2017)
  • Figure 90 : Pfizer Inc’s Breakdown of Net Sales, by Region, 2017
  • Figure 92 : Pfizer Inc’s R&D Intensity and Sales & Marketing Intensity - Company Level, 2016–2017
  • Figure 93 : Eli Lilly’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 94 : Eli Lilly’s Breakdown of Net Sales (%), by Region, 2017
  • Figure 95 : Eli Lilly’s Research & Development Cost (US$ Mn), 2016 and 2017
  • Figure 96 : Eli Lilly’s Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 97 : UCB, Inc’s Breakdown of Net Sales, by Region
  • Figure 98 : UCB, Inc’s Breakdown of Net Sales, by Therapeutic Area
  • Figure 99 : UCB, Inc’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 100 : UCB, Inc’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 101 : Biogen Inc’s Breakdown of Net Revenue, by Region
  • Figure 102 : Biogen Inc’s Breakdown of Net Sales, by Revenue Center
  • Figure 103 : Biogen Inc’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2017
  • Figure 104 : Biogen Inc’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
  • Figure 105 : Bristol-Myers Squibb Company’s Revenue (US$ Bn), 2014-2017
  • Figure 106 : Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
  • Figure 107 : Bristol-Myers Squibb Company Revenue, by Geography, 2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us